Healthcare

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Small Molecule Sterile Injectable Drugs Market – Industry Trends and Forecast to 2028

Healthcare | Published Report | Aug 2021 | MEA | 350 Pages | No of Tables: 59 | No of Figures: 38

Report Description

Middle East and Africa Small Molecule Sterile Injectable Drugs Market, By Product (Vial Filling, Syringe Filling, Cartridge Filling and Others), Application (Oncology, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Neurology, Dermatology, Urology, Autoimmune Diseases, Respiratory Disorders and Others), End-Users (Hospitals, Specialty Clinics, Home Care Settings and Others), Distribution Channels (Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Country (Saudi Arabia, South Africa, UAE, Israel, Egypt, Ethiopia and Rest of the Middle East and Africa) Industry Trends and Forecast to 2028.

Market Analysis and Insights: Middle East and Africa Small Molecule Sterile Injectable Drugs Market

The small molecule sterile injectable drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.1% in the forecast period of 2021 to 2028 and is expected to reach USD 5,642.25 million by 2028. Growing prevalence of chronic diseases is expected to drive the growth of the small molecule sterile injectable drugs market.

Injectable drugs delivery is a process that involves the administration of a drugs or combination of drugs into the patient's body by using various delivery devices such as syringes and needles. Sterile injectable drugs are frequently prepared in liquid form due to the easy transportation of drugs directly into systematic blood circulation. Sometimes, they may be prepared to transport the drugs to a specific part of the body.

Growth in generic injectable is boosting the growth of the small molecule sterile injectable drugs market. Increasing product recalls are restraining the growth of the small molecule sterile injectable drugs market. Rising healthcare expenditure is acting as an opportunity for the small molecule sterile injectable drugs market growth. Lack of accessibility is a challenge for the small molecule sterile injectable drugs market.

The small molecule sterile injectable drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the small molecule sterile injectable drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Small Molecule Sterile Injectable Drugs Market Scope and Market Size

The small molecule sterile injectable drugs market is segmented based on the product, application, end-users and distribution channels. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the small molecule sterile injectable drugs market is segmented into vial filling, syringe filling, cartridge filling and others. In 2021, the vial filling segment is expected to dominate the small molecule sterile injectable drugs market due to rising technological advancement in small molecule sterile injectable drugs.
  • On the basis of application, the small molecule sterile injectable drugs market is segmented into oncology, infectious diseases, cardiovascular diseases, metabolic diseases, neurology, dermatology, urology, autoimmune diseases, respiratory disorders and others. In 2021, the oncology segment is expected to dominate the small molecule sterile injectable drugs market due to the rising number of patient pool suffering from cancer.
  • On the basis of end-users, the small molecule sterile injectable drugs market is segmented into hospitals, specialty clinics, home care settings and others. In 2021, the hospitals' segment is expected to dominate the small molecule sterile injectable drugs market due to the rising number of hospitals in developing countries.
  • On the basis of distribution channels, the small molecule sterile injectable drugs market is segmented into direct tender, retail pharmacy, online pharmacy and others. In 2021, the direct tender segment is expected to dominate the small molecule sterile injectable drugs market because the direct tender option is mostly used by the large channel hospital for purchasing small molecule sterile injectable products.

Middle East and Africa Small Molecule Sterile Injectable Drugs Market Country Level Analysis

Middle East and Africa small molecule sterile injectable drugs market is analyzed and market size information is provided by the country, product, application, end-users and distribution channels as referenced above.

The countries covered in Middle East and Africa small molecule sterile injectable drugs market report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, Ethiopia and rest of the Middle East and Africa.

Saudi Arabia is expected to lead the growth of the Middle East and Africa small molecule sterile injectable drugs market as vial filling segment is expected to dominate in the country due to presence of the highest number of small molecule sterile injectable drugs providers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Small Molecule Sterile Injectable Drugs is boosting the Small Molecule Sterile Injectable Drugs Market Growth

The small molecule sterile injectable drugs market also provides you with detailed market analysis for every country growth in small molecule sterile injectable drugs market. Additionally, it provides the detail information regarding the small molecule sterile injectable drugs market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.

Competitive Landscape and Small Molecule Sterile Injectable Drugs Market Share Analysis

The small molecule sterile injectable drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Middle East and Africa small molecule sterile injectable drugs market.

The major companies which are dealing in the Middle East and Africa small molecule sterile injectable drugs market report are Gilead Sciences, Inc., AstraZeneca, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Hikma Pharmaceuticals PLC, AbbVie Inc., American Regent, Inc. (a Daiichii Sankyo Group Company), Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the small molecule sterile injectable drugs market.

For instance,

  • In May 2020, AbbVie Inc. acquired Allergan, a global company focused on manufacturing products targeting neuroscience, urology among other medical fields. This acquisition allowed the company to enhance its therapeutic categories and strengthen the company's financial values, which ultimately accelerated the company's research and developmental activities.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company footprints in the small molecule sterile injectable drugs market which also provides the benefit for organization’s profit growth.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S ANALYSIS

5 REGULATORY FRAMEWORK

5.1 REGULATORY GUIDANCE AS PER U.S. FDA.

5.2 REGULATORY SCENARIO FOR EUROPEAN UNION

5.3 REGULATORY SCENARIO IN JAPAN

5.4 REGULATORY FRAMEWORK IN CHINA

6 PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

7.1.2 PRODUCT APPROVAL OF SMALL MOLECULE

7.1.3 HIGH R&D INVESTMENT FOR SMALL MOLECULE DEVELOPEMNT

7.1.4 STRONG PIPELINE FOR SMALL MOLECULE INJECTABLE

7.1.5 GROWTH IN GENERIC INJECTABLES

7.2 RESTRAINTS

7.2.1 HIGH LEVEL OF QUALITY AND CARE REQUIRED IN THE PRODUCTION

7.2.2 HIGH MANUFACTURING AND PURCHASING COST OF INJECTABLES

7.2.3 STRINGENT REGULATIONS FOR FACILITES AND EQUIPMENTS REQUIRED FOR SMALL MOLECULES INJECTABLE

7.2.4 PRODUCT RECALL

7.3 OPPORTUNITIES

7.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

7.3.2 GROWING PRODUCT LAUNCHES

7.3.3 RISING PER CAPTIA INCOME AND HEALTHCARE EXPENDITURE

7.4 CHALLENGES

7.4.1 LACK OF ACCESSIBILITY

7.4.2 HIGH COST OF DIAGNOSIS & TREATMENT

8 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET

8.1 OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE

8.2 IMPACT ON PRICE

8.3 IMPACT ON DEMAND

8.4 IMPACT ON SUPPLY CHAIN

8.5 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

8.6 CONCLUSION

9 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 VIAL FILLING

9.3 SYRINGE FILLING

9.4 CARTRIDGE FILLING

9.5 OTHERS

10 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 ONCOLOGY

10.3 INFECTIOUS DISEASES

10.4 CARDIOVASCULAR DISEASES

10.5 METABOLIC DISEASES

10.6 NEUROLOGY

10.7 UROLOGY

10.8 DERMATOLOGY

10.9 AUTOIMMUNE DISEASES

10.1 RESPIRATORY DISORDERS

10.11 OTHERS

11 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

11.4 HOMECARE SETTING

11.5 OTHERS

12 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

12.5 OTHERS

13 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E.

13.1.4 EGYPT

13.1.5 ISRAEL

13.1.6 ETHIOPIA

13.1.7 REST OF MIDDLE EAST & AFRICA

14 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 PFIZER INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 SERVICE PORTFOLIO

16.2 GILEAD SCIENCES, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 FRESENIUS KABI USA (ASUBSIDIARY OF FRESENIUS SE & CO. KGAA).

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 ABBVIE INC.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 AMERICAN REGENT, INC. (A DAIICHI SANKYO GROUP COMPANY)

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 AMGEN INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 AMOMED PHARMA GMBH

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENTS

16.9 ASTRAZENECA

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 BIOCRYST PHARMACEUTICALS, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 BRISTOL-MYERS SQUIBB COMPANY

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 EISAI CO., LTD.

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

16.13 EXELIXIS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 HIKMA PHARMACEUTICALS PLC

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENTS

16.17 NEUREN PHARMACEUTICALS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 NOXOPHARM

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENTS

16.19 SANOFI

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TELIGENT

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, PIPELINE ANALYSIS

TABLE 2 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS

TABLE 3 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)

TABLE 4 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA VIAL FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA SYRINGE FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA CARTRIDGE FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA ONCOLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASE IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA METABOLIC DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA NEUROLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA UROLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA DERMATOLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA RESPIRATORY DISORDERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA HOSPITALS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA HOMECARE SETTING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA DIRECT TENDER IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 35 SOUTH AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 36 SOUTH AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 SOUTH AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 SOUTH AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 SAUDI ARABIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 40 SAUDI ARABIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 41 SAUDI ARABIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 42 SAUDI ARABIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 U.A.E. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 44 U.A.E. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 45 U.A.E. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 U.A.E. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 EGYPT SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 48 EGYPT SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 49 EGYPT SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 50 EGYPT SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 ISRAEL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 52 ISRAEL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 53 ISRAEL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 ISRAEL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 ETHIOPIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 56 ETHIOPIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 57 ETHIOPIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 58 ETHIOPIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 59 REST OF MIDDLE EAST & AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: PRODUCT LIFELINE CURVE

FIGURE 8 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 10 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 12 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 13 THE GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF MIDDLE EAST AND AFRICA IMMUNOASSAYS-GAMMA COUNTER MARKET

FIGURE 16 THE GRAPH BELOW SHOWS THE INCREASING PREVALENCE OF CHRONIC DISEASES IN 1995 TO FORECAST 2030 IN THE U.S.

FIGURE 17 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2020

FIGURE 18 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 20 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2020

FIGURE 22 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 26 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 30 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 34 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 35 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 37 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT (2021-2028)

FIGURE 38 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: PRODUCT LIFELINE CURVE

FIGURE 8 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 10 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 12 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 13 THE GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF MIDDLE EAST AND AFRICA IMMUNOASSAYS-GAMMA COUNTER MARKET

FIGURE 16 THE GRAPH BELOW SHOWS THE INCREASING PREVALENCE OF CHRONIC DISEASES IN 1995 TO FORECAST 2030 IN THE U.S.

FIGURE 17 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2020

FIGURE 18 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 20 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2020

FIGURE 22 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 26 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 30 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 34 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 35 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 37 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT (2021-2028)

FIGURE 38 MIDDLE EAST AND AFRICA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19